Popular Articles

Commercialization Grant Awards Announced By Life Sciences Discovery Fund
The Life Sciences Discovery Fund (LSDF) has announced $300,000 in awards from its inaugural winter commercialization grant competition to support commercial translation of health-related technologies by two Washington state-based research teams. Commercialization grants are designed to facilitate the transition of promising ideas or technologies from Washington"s non-profit research sector into marketable products and services that can improve health, foster economic growth, and promote life sciences competitiveness in the state. The grants support proof-of-concept experiments and prototype development activities that are expected to lower the risk of commercialization and help new technologies cross the "valley of death" - that stage of the commercialization pathway where development funding is particularly scarce.

Pilot Study Confirms That Children With Autism Need To Be Taught In Smaller Groups
Since the 1970s, there has been much debate surrounding the fact that individuals with autism have difficulty in understanding speech in situations where there is background speech or noise.
News of the day
Phase III Study Showed Lucentis Improved Vision In Patients With Branch Retinal Vein Occlusion
Genentech, Inc. announced today that the Phase III study BRAVO showed Lucentis® (ranibizumab injection) improved vision, as measured by the primary endpoint of mean change from baseline in best-corrected visual acuity at six months, in patients with macular edema due to branch retinal vein occlusion. The safety profile of Lucentis was consistent with previous experience and no new adverse events related to Lucentis were observed in the study. Retinal vein occlusion (RVO) is a common cause of vision loss that occurs when blood flow through a retinal vein becomes blocked, such as by a blood clot.
Public Health

Perceived Cancer Risks May Not Reflect Actual Risks Or Prevention Needs

Working with a population of individuals at risk for gastrointestinal cancers, researchers at Fox Chase Cancer Center have learned that many people misjudge their actual degree of cancer risk and, therefore, their true need for prevention support. Strategies for accurately assessing cancer risk are critical for appropriately targeting educational, counseling, and diagnostic res to prevent cancer in as many individuals as possible, the investigators say. The study, to be presented at the 2009 Annual Meeting of the American Society of Clinical Oncology, evaluated participants in the Gastrointestinal Tumor Risk Assessment Program at Fox Chase. With the growth in genetic cancer risk assessment in recent years, Fox Chase clinicians and scientists have seen increasing numbers of patients enrolling in the Center"s risk assessment programs, including those for breast, ovarian, melanoma, prostate, and gastrointestinal cancers. Risk for gastrointestinal cancers, the focus of the current study, is established through family and personal histories of gastrointestinal cancers and/or colorectal polyps, as well as genetic testing. "The goal of our study was to improve how we think about and direct our prevention res," says Michael Hall, M.D., medical oncologist at Fox Chase and lead author on the study. "We examined clinical cancer prevention needs among individuals seeking gastrointestinal risk evaluation, including in our assessment their estimated personal risk, risk beliefs, and interest in genetic testing." The study evaluated 398 individuals from 278 families enrolled in the Gastrointestinal Tumor Risk Assessment Program at Fox Chase over a nine-year period. The program provides risk assessment to people seeking evaluation for a risk of a gastrointestinal or related cancer. Participants were required to sign an informed consent and complete a health history questionnaire prior to counseling, education, and genetic services. Results showed that more than 17 percent of the individuals were at high-risk; 70 percent were at moderate-to-high risk; and 12 percent were at low-risk. "One of our main findings was that, prior to counseling, individuals in the low-risk group estimated the magnitude of their cancer risk as equal to that of the high-risk group," Hall notes. "Clearly, the first step in offering clinical prevention tools to all of the individuals entering our risk assessment program is to help them to understand their actual level of risk. Only then can we recommend the appropriate prevention support." In the Fox Chase Gastrointestinal Tumor Risk Assessment Program, low-risk individuals receive risk-factor management counseling and education related to appropriate screening. Those at moderate-to-high or high risk are offered additional prevention tools, such as intensive screening and prophylactic surgery, chemoprevention, and genetic testing. "Preventing cancer is as important as treating cancer," says Hall, summing up his team"s findings. "As information about the genetic causes of many cancers becomes more widely known, motivated people with a varying levels of concern and need come to us for risk assessment. To best serve them, we must be able to gauge their risk accurately in order to maximize the benefits of the prevention tools we offer." Abstract #1539: Diverse cancer prevention needs in a population seeking risk assessment for gastrointestinal (GI) cancers. General Poster Session, Sunday, May 31, 2:00 p.m.-6:00 p.m. - Level 2, West Hall C Diana Quattrone Fox Chase Cancer Center


Add your comment:
Name:
Site address: http://
Your message:
Enter today\\\\'s date, 2 digits
(spam protection):